Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director · President and CEO | March 14, 2025 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date March 14, 2025 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 135,944 |
Ending reported balance
After 2026-03-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-13 · Exercise / conversion · Acquired 33,500 · Balance 150,497 Row 2 · 2026-03-13 · Tax withholding · Disposed 14,553 · Balance 135,944 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 134,000 |
Reported balance
After 2025-03-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-14 · Grant · Acquired 134,000 · Balance 134,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 278,000 |
Reported balance
After 2026-03-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-13 · Grant · Acquired 278,000 · Balance 278,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 100,500 |
Reported balance
After 2026-03-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-13 · Exercise / conversion · Disposed 33,500 · Balance 100,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2035-03-14 | Direct | 153,000 |
Reported balance
After 2025-03-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-14 · Grant · Acquired 153,000 · Balance 153,000 F2: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.62 · Expires 2036-03-13 | Direct | 309,000 |
Reported balance
After 2026-03-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-13 · Grant · Acquired 309,000 · Balance 309,000 F3: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
F3: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2026 Filed Mar 17, 2026 17:00 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 33,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002005474-26-000004 · wk-form4_1773781219.xml · derivative · entry 7 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,500 Underlying: Class A Common Stock · 33,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 17:00 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 309,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0002005474-26-000004 · wk-form4_1773781219.xml · derivative · entry 6 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,000 Underlying: Class A Common Stock · 309,000 shares Expires 2036-03-13 F3 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 17:00 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 278,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002005474-26-000004 · wk-form4_1773781219.xml · derivative · entry 5 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,000 Underlying: Class A Common Stock · 278,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 17:00 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 14,553 | $8.62 | $125,446.86 |
DisclosureSEC source: 0002005474-26-000004 · wk-form4_1773781219.xml · nonDerivative · entry 2 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,944 Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 17:00 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 33,500 | $0.00 | $0.00 |
DisclosureSEC source: 0002005474-26-000004 · wk-form4_1773781219.xml · nonDerivative · entry 1 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 17:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002005474-26-000002 · wk-form4_1768343397.xml · derivative · entry 3 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Class A Common Stock · 93,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 17:30 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 41,717 | $8.03 | $334,987.51 |
DisclosureSEC source: 0002005474-26-000002 · wk-form4_1768343397.xml · nonDerivative · entry 2 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,997 Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 17:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002005474-26-000002 · wk-form4_1768343397.xml · nonDerivative · entry 1 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2025 Filed Mar 17, 2026 17:00 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 153,000 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0002005474-26-000004 · wk-form4_1773781219.xml · derivative · entry 4 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,000 Underlying: Class A Common Stock · 153,000 shares Expires 2035-03-14 F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| March 14, 2025 Filed Mar 17, 2026 17:00 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 134,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002005474-26-000004 · wk-form4_1773781219.xml · derivative · entry 3 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,000 Underlying: Class A Common Stock · 134,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 18:59 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 28,786 | $9.10 | $261,952.60 |
DisclosureSEC source: 0001578563-25-000023 · wk-form4_1736899184.xml · nonDerivative · entry 1 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,964 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on January 10, 2025 pursuant to a standing 10b5-1 instruction adopted on January 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.935 to $9.22, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 17:24 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000015 · primary_doc.xml · derivative · entry 2 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,250 Underlying: Class A Common Stock · 93,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 17:24 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000015 · primary_doc.xml · nonDerivative · entry 1 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 16:52 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 850,000 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001578563-24-000014 · primary_doc.xml · derivative · entry 2 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 Underlying: Class A Common Stock · 850,000 shares Expires 2034-01-11 F2 · derivative.exercise_date: The restricted stock units and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 16:52 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 375,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000014 · primary_doc.xml · derivative · entry 1 Claypoole Robert E · CIK 0002005474 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Class A Common Stock · 375,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.